Inoue A, Yamazaki J, Nanjou S, Togane Y, Amano H
First Department of Internal Medicine, Ohmori Hospital, Toho University School of Medicine.
Kaku Igaku. 2001 Mar;38(2):99-104.
We investigated prediction of the efficacy of beta-blocker therapy in patients with dilated cardiomyopathy (DCM) by using myocardial scintigraphy with 123I-BMIPP (BMIPP) and 123I-MIBG (MIBG). Thirty-seven patients with DCM were examined by myocardial scintigraphy with BMIPP and MIBG before beta-blocker therapy. Patients were classified into two groups, based on whether they improved > 10% of the left ventricular ejection fraction (LVEF) (improved group, n = 21) or not (unimproved group, n = 16). The extent and severity score of BMIPP for the improved group was significantly lower (p < 0.001) than that for unimproved group. It has been suggested that BMIPP is useful in evaluating the prediction of efficacy of beta-blocker therapy in patients with DCM.
我们通过使用123I-苄基十五烷酸（BMIPP）和123I-间碘苄胍（MIBG）心肌闪烁显像，研究了β受体阻滞剂治疗扩张型心肌病（DCM）患者的疗效预测情况。37例DCM患者在接受β受体阻滞剂治疗前，接受了BMIPP和MIBG心肌闪烁显像检查。根据左心室射血分数（LVEF）是否提高>10%，将患者分为两组（改善组，n = 21；未改善组，n = 16）。改善组BMIPP的范围和严重程度评分显著低于未改善组（p < 0.001）。提示BMIPP有助于评估β受体阻滞剂治疗DCM患者疗效的预测情况。
